| Autor: |
Suzanne, Nguyen, Christine, Rebischung, Johan, Van Ongeval, Michel, Flesch, Mustapha, Bennamoun, Thierry, André, Marc, Ychou, Erik, Gamelin, Elisabeth, Carola, Christophe, Louvet |
| Rok vydání: |
2006 |
| Předmět: |
|
| Zdroj: |
Bulletin du cancer. 93(1) |
| ISSN: |
1769-6917 |
| Popis: |
We evaluated the Epitax combination (epirubicin 60 mg/m2 and docetaxel 75 mg/m2, every 3 weeks) in advanced gastric cancer (AGC) as second-line treatment after fluorouracil and platinum in 50 patients, then as first-line treatment in 36 patients. We report here the results of these two phase II studies.In the second-line treatment, the response rate (RR) was 15.5%. Grade 3-4 neutropenia was observed in 68% (febrile neutropenia in 40%, one treatment-related death). Median time to progression (TTP) and overall survival (OS) were 2.4 and 5.0 months, respectively. In the first-line treatment, the RR was 19.4%. With prophylactic granulocyte colony-stimulating factor, grade 3-4 neutropenia was reported in 38.9%. Then 22 patients received a second-line and 11 patients a third-line treatment. Median TTP and OS were 4.5 and 12 months, respectively.Epitax showed moderate activity in AGC. RR in both trials suggests a non-cross resistance with fluorouracil/platinum combination. The 12-month OS in the first-line treatment could be partly explained by early evaluation and active non-cross resistant second-line therapy. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
